Cover Image
市場調查報告書

腮腺炎 : 開發平台分析

Mumps - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 271822
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
腮腺炎 : 開發平台分析 Mumps - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 33 Pages
簡介

腮腺炎是病毒性的接觸感染疾病,產生伴隨唾液腺疼痛的腫脹。病原病毒由個人間的對飛沫感染(鼻涕等),和沾有病毒的唾液之物直接接觸等方式擴大。主要的症狀為,發熱和臉的疼痛,頭痛,喉嚨的疼痛,太陽穴和下巴發腫,耳下腺的腫脹等。主要的治療方法有(緩和症狀)止痛藥等。

本報告提供全球各國的腮腺炎(流行性腮腺炎)治療用的開發中產品的開發情形相關分析、開發中產品的開發、上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

腮腺炎概要

治療藥的開發

  • 腮腺炎開發中產品:概要
  • 腮腺炎開發中產品:比較分析

各企業開發中的腮腺炎治療藥

大學/研究機關研究中的腮腺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

腮腺炎治療藥:開發中的產品一覽(各企業)

腮腺炎治療藥:研究中的產品一覽(大學/研究機關)

腮腺炎治療藥開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • China National Pharmaceutical Group Corporation
  • GlaxoSmithKline Plc
  • Organic Vaccines
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

腮腺炎:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各投藥法
  • 各分子類型

藥物簡介

  • 麻疹、腮腺炎、德國麻疹(MMR)細胞療法
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • MMR+水痘疫苗
  • MMR活病毒疫苗(新三種混合疫苗)
  • 麻疹strain schwarz 、腮腺炎strain RIT 4385、德國麻疹strain wistar RA 27/3疫苗
  • 腮腺炎疫苗

腮腺炎治療藥:開發中產品的最新趨勢

腮腺炎治療藥:開發暫停的產品

腮腺炎相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9000IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H1 2017, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mumps - Overview
  • Mumps - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Mumps - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Mumps - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Beijing Tiantan Biological Products Co Ltd
    • Daiichi Sankyo Company Ltd
    • GlaxoSmithKline Plc
    • Prometheon Pharma LLC
    • Sinovac Biotech Ltd
    • Zydus Cadila Healthcare Ltd
  • Mumps - Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mumps - Dormant Projects
  • Mumps - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mumps, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Mumps - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2017
  • Mumps - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Mumps - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Mumps - Pipeline by Prometheon Pharma LLC, H1 2017
  • Mumps - Pipeline by Sinovac Biotech Ltd, H1 2017
  • Mumps - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Mumps - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Mumps, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top